NINDS Neuroscience Funding Announcements

The National Institute of Neurological Disorders and Stroke (NINDS) has a requirement to accelerate neuroprotective therapeutics development for Parkinson's Disease (PD). PD is the second most commonly occurring neurodegenerative disease, hallmarked by the gradual loss of dopaminergic and other neurons, as well as the accumulation of insoluble aggregates. Therefore, a primary goal is to find rational treatments which can prevent progression of the disease once diagnosed or prevent neurons from dying in individuals at risk for developing the disease.